Peer-reviewed veterinary case report
Risk of low adrenal function in dogs treated with trilostane
By King, J B & Morton, J M·Published in Veterinary journal (London, England : 1997)·2017·Veterinary Specialist Services, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Incidence and risk factors for hypoadrenocorticism in dogs treated with trilostane.
- Species:
- dog
Plain-English summary
A group of dogs being treated with trilostane for Cushing's disease (hyperadrenocorticism) developed a condition called hypoadrenocorticism, which means their adrenal glands weren't producing enough hormones. About 15% of these dogs experienced this issue within the first two years, and around 26% by four years. Most cases were temporary, resolving on their own. The study found that increasing the dose of trilostane only slightly raised the risk of this side effect. If your dog is on trilostane, it's important to monitor for symptoms like lethargy or vomiting and discuss any concerns with your vet.
People also search for: dog Cushing's disease treatment · trilostane side effects in dogs · symptoms of hypoadrenocorticism in dogs
Abstract
The aim of this study was to describe the incidence and permanence of hypoadrenocorticism associated with trilostane treatment and to assess potential risk factors for hypoadrenocorticism. A retrospective cohort study was conducted using case records for 156 dogs treated with trilostane after a diagnosis of hyperadrenocorticism. Occurrences of hypoadrenocorticism were categorised as either transient or permanent. After initiation of treatment with trilostane, the estimated cumulative incidence of hypoadrenocorticism was 15% by 2 years and 26% by 4.3 years, respectively. Occurrences of hypoadrenocorticism were transient in 14/19 (74%) affected study dogs. The risk of hypoadrenocorticism was not significantly associated with trilostane dose rate and other potential risk factors assessed were not significantly associated with subhazard of hypoadrenocorticism, but effect estimates for most were imprecise. In conclusion, approximately 15% of dogs being treated with trilostane developed hypoadrenocorticism within the first 2 years of treatment and about one quarter became affected by 4 years. However, first occurrences of hypoadrenocorticism were mostly transient. Over the range of dose rates studied, each 1mg/kg/day increase in trilostane dose rate resulted in, at most, only a small increase in the risk of developing hypoadrenocorticism.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/29208212/